Sector News

FDA creating innovation office to speed drug development

January 9, 2019
Life sciences

The FDA is creating an office of drug development science to cut the cost of bringing new medicines to patients, BioCentury reports. Staff at the office will create tools that sponsors and the FDA can use to streamline the development and regulatory assessment of drugs.

FDA Commissioner Scott Gottlieb, M.D., is due to reveal the new office later Tuesday via videolink at the J.P. Morgan Healthcare Conference. In creating the office, Gottlieb thinks the FDA can leverage improved understanding of biomarkers and other advances to build tools that take some of the risks and costs out of drug development.

“The whole reason for the cost of drug development is high is that the science of prediction is costly and uncertain,” Gottlieb told BioCentury. “We believe the time has come to make the science of drug development a more formal scientific discipline within the new drug approval process, along with the components that it comprises.”

In practice, that belief will manifest in 51-person Office of Drug Evaluation Science made up of groups focused on clinical outcome assessments, biomedical informatics and safety analytics and biomarker development.

Around one-fifth of the office’s workforce will focus on creating more structured approaches to the evaluation of biomarkers, which Gottlieb thinks are ready to play a “much more formal” role in drug development and review. One strand of the biomarker unit’s activities will seek to develop standards in collaboration with drug developers, academics and other stakeholders.

Another third of the office’s 51 employees will work on biomedical informatics and safety analytics. Gottlieb said these staff will build “a standardized tool for capturing and formatting safety data” to make the agency’s reviews of safety data more structured and consistent.

If the initiative advances as hoped, it will serve as a stepping stone to a new way of managing drug application reviews. The new approach foreseen by Gottlieb will build on advances in data handling and cloud computing to give the FDA a more active role in how the information underpinning filings is presented and evaluated.

“Applications will be cloud based and instead of taking the sponsors’ charts and tables and evaluating their charts and tables, we’ll be pulling down their bottom line data and formatting it through our own assessment tools and creating our own charts and tables to do the evaluation,” Gottlieb said.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

September 26, 2021

Lonza invests to expand drug product development and manufacturing services in Switzerland

Life sciences

Lonza will invest to expand its drug product manufacturing network in Switzerland. The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel. The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp.

September 26, 2021

Repairing heart damage by transiently turning back the clock

Life sciences

Partial reprogramming of adult heart cells to a fetal-like state could help repair heart damage following cardiac injury or disease, scientists at the Max Planck Institute for Heart and Lung Research showed in mice. 

September 26, 2021

Merck women’s health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy

Life sciences

When Merck’s women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is getting specific. Organon hopes to ignite a conversation about an issue that affects 121 million women around the world every year.

Send this to a friend